.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Harvard Business School
Covington
Mallinckrodt
Accenture
Cantor Fitzgerald
Moodys
Daiichi Sankyo
US Department of Justice
Chubb

Generated: September 21, 2017

DrugPatentWatch Database Preview

LYGEN Drug Profile

« Back to Dashboard

Which patents cover Lygen, and what generic Lygen alternatives are available?

Lygen is a drug marketed by Alra and is included in three NDAs.

The generic ingredient in LYGEN is chlordiazepoxide hydrochloride. There are eight drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the chlordiazepoxide hydrochloride profile page.

Summary for Tradename: LYGEN

Patents:0
Applicants:1
NDAs:3
Bulk Api Vendors: see list34
Patent Applications: see list1,785
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:LYGEN at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alra
LYGEN
chlordiazepoxide hydrochloride
CAPSULE;ORAL085107-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Alra
LYGEN
chlordiazepoxide hydrochloride
CAPSULE;ORAL085108-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Alra
LYGEN
chlordiazepoxide hydrochloride
CAPSULE;ORAL085009-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Baxter
Daiichi Sankyo
Citi
Fish and Richardson
Dow
Mallinckrodt
Cantor Fitzgerald
Cerilliant
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot